Trovera liquid biopsy tests provide actionable information about EGFR, KRAS and BRAF mutations, often associated with common solid tumor cancers, to aid you in choosing the right treatment for the right patient at the right time.
The Trovera Difference
Clinically Actionable Results
Trovagene focuses on actionable mutations, well documented in treatment guidelines, helping physicians select from among the most appropriate therapies available.
Ultra-Sensitive Mutation Detection
Trovagene’s proprietary technology enables industry-leading sensitivity with detection as low as 0.006%, or ten times greater than other currently available liquid biopsy methods. This sensitivity is the equivalent of detecting one cancer cell per 20,000 non cancer cells.
Quantitative Results Reporting
Trovera quantitative test results enable tracking of mutation levels and trends before, during and after treatment intervention.
Noninvasive and Convenient Testing
Trovera liquid biopsies, utilizing urine and blood allow for easy and frequent assessment of mutational status without the need for invasive, more time consuming procedures. Urine is the epitome of a noninvasive, replenishable and convenient ctDNA source.